← Back to home

CASTRATION-RESISTANT PROSTATE CARCINOMA REFRACTORY TO SECOND-GENERATION ANDROGEN RECEPTOR AXIS-TARGETED AGENTS

Clinical trials for CASTRATION-RESISTANT PROSTATE CARCINOMA REFRACTORY TO SECOND-GENERATION ANDROGEN RECEPTOR AXIS-TARGETED AGENTS explained in plain language.

Never miss a new study

Get alerted when new CASTRATION-RESISTANT PROSTATE CARCINOMA REFRACTORY TO SECOND-GENERATION ANDROGEN RECEPTOR AXIS-TARGETED AGENTS trials appear

Sign up with your email to follow new studies for CASTRATION-RESISTANT PROSTATE CARCINOMA REFRACTORY TO SECOND-GENERATION ANDROGEN RECEPTOR AXIS-TARGETED AGENTS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Terminated 1

Drug trial halted early for advanced prostate cancer

Disease control Terminated

This study tested whether a drug called erdafitinib could help control advanced prostate cancer that had stopped responding to standard hormone treatments and spread to the bones. It involved 11 men and aimed to see if the drug could slow cancer growth and reduce bone-related mar…

Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA REFRACTORY TO SECOND-GENERATION ANDROGEN RECEPTOR AXIS-TARGETED AGENTS

Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control

Last updated Mar 25, 2026 14:08 UTC

CASTRATION-RESISTANT PROSTATE CARCINOMA REFRACTORY TO SECOND-GENERATION ANDROGEN RECEPTOR AXIS-TARGETED AGENTS

Get alerted when new CASTRATION-RESISTANT PROSTATE CARCINOMA REFRACTORY TO SECOND-GENERATION ANDROGEN RECEPTOR AXIS-TARGETED AGENTS trials appear

Drug trial halted early for advanced prostate cancer